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Background: Opioid peptides, including dynorphin A, besides their analgesic action in the nervous system, exert a
broad spectrum of effects on cells of the immune system, including leukocyte migration, degranulation and cytokine
production. The mechanisms whereby opioid peptides induce leukocyte responses are poorly understood. The integrin
Mac-1 (αMβ2, CD11b/CD18) is a multiligand receptor which mediates numerous reactions of neutrophils and monocyte/
macrophages during the immune-inflammatory response. Our recent elucidation of the ligand recognition specificity of
Mac-1 suggested that dynorphin A and dynorphin B contain Mac-1 recognition motifs and can potentially interact with
this receptor.
Results: In this study, we have synthesized the peptide library spanning the sequence of dynorphin AB, containing
dynorphin A and B, and showed that the peptides bound recombinant αMI-domain, the ligand binding region of
Mac-1. In addition, immobilized dynorphins A and B supported adhesion of the Mac-1-expressing cells. In binding
to dynorphins A and B, Mac-1 cooperated with cell surface proteoglycans since both anti-Mac-1 function-blocking
reagents and heparin were required to block adhesion. Further focusing on dynorphin A, we showed that its interaction
with the αMI-domain was activation independent as both the α7 helix-truncated (active conformation) and
helix-extended (nonactive conformation) αMI-domains efficiently bound dynorphin A. Dynorphin A induced a potent
migratory response of Mac-1-expressing, but not Mac-1-deficient leukocytes, and enhanced Mac-1-mediated
phagocytosis of latex beads by murine IC-21 macrophages.
Conclusions: Together, the results identify dynorphins A and B as novel ligands for Mac-1 and suggest a role for
the Dynorphin A-Mac-1 interactions in the induction of nonopiod receptor-dependent effects in leukocytes.
Keywords: Dynorphin A, Integrin Mac-1 (CD11b/CD18), Leukocytes, Opioid peptides, Adhesion moleculesBackground
Dynorphins are endogeneous opioid peptides released from
injured neurons. By binding to the G-protein-coupled κ-
opioid receptors found throughout the central and periph-
eral nervous systems they exert protective analgesic effects.
At pathophysiological conditions, however, in which the
dynorphin concentrations are elevated, these peptides may
induce proalgesic effects and contribute to neurodegenera-
tion largely acting at glutamate receptors (Reviewed in [1]).
In addition to neurons, dynorphins are synthesized and re-
leased by stimulated leukocytes, including resident im-
mune cells and cells that migrate to inflamed tissues from* Correspondence: Nataly.Podolnikova@asu.edu
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creativecommons.org/publicdomain/zero/1.0/circulation (Reviewed in [2–4]). Since tissue injury is asso-
ciated with an inflammatory reaction and pain, secretion of
leukocyte-derived opioid peptides, including dynorphins,
and their interaction with opioid receptors on peripheral
sensory neurons presents an important mechanism that
contributes to counteracting inflammatory pain [4].
Dynorphin A (Dyn A) is one of several processed
neuropeptides (collectively referred to as “dynorphins”)
derived from the prodynorphin protein. Although the
mechanism for prodynorphin processing in leukocytes
has not been fully elucidated, in neurons the proprotein
is cleaved by convertases, primarily PC2, resulting in the
generation of dynorphin AB (Dyn AB; also known as
“big dynorphin”) consisting of Dyn A (residues 1–17) and
dynorphin B (Dyn B; residues 20–32). Dyn A can beess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Podolnikova et al. Molecular Pain  (2015) 11:33 Page 2 of 16cleaved further, giving rise to shorter peptides, for example
Dyn A (1–8).
Apart from their effects on κ-opioid receptors on
neurons, Dyn A exerts numerous effects on leukocytes,
particularly myeloid cells. Dyn A has been shown to
increase secretion of IL-1 and TNFα by macrophages [5,
6], enhance phagocytosis by mouse peritoneal macro-
phages [7], stimulate macrophage superoxide generation
[8], enhance macrophage zymosan-triggered oxidative
burst [9], decrease nitric oxide release induced by LPS
and IFN-γ [10] and induce degranulation and histamine
release from rat mast cells [11–13]. In addition, Dyn A
(residues 1–13) and Dyn A (residues 1–9) stimulate
human mononuclear cell and neutrophil chemotaxis [14,
15]. Opioid receptors have been demonstrated in im-
mune cells (Reviewed in [4]). However, even though
some of the observed effects of Dyn A are mediated by
opioid receptors, such responses as phagocytosis, de-
granulation and chemotaxis could not be blocked or
were blocked partially by naloxone, the classical opioid
receptor antagonist [7, 11, 15]. These results imply that
both opioid and nonopiod receptors may be involved.
The integrin αMβ2 (Mac-1, CD11b/CD18) is the major
receptor expressed on the surface of phagocytic leuko-
cytes, which mediates numerous cellular responses of
these cells during the immune-inflammatory response.
Ligand engagement by Mac-1 initiates phagocytosis, mi-
gration, degranulation, and expression of cytokines and
other bioactive molecules [16]. A remarkable feature of
Mac-1 is its ability to bind a multitude of diverse ligands.
We have recently determined a unifying principle that
governs the broad ligand binding specificity exhibited by
Mac-1. We showed that the αMI-domain, a ligand bind-
ing region of Mac-1, recognizes short sequences con-
taining positively charged and hydrophobic residues that
are present in many Mac-1 ligands. The Mac-1 recogni-
tion sequences are exemplified by HyBHy, HyHyBHy,
HyBHyHy and HyHyBHyHy motifs, where Hy repre-
sents any hydrophobic residue and B is basic residues
with a preference for Arg [17]. Furthermore, negatively
charged and polar residues are depleted in the αMI-
domain binders. We further proposed that cationic pro-
teins and peptides, which are stored in myeloid cells and
remarkably enriched in such motifs, represent a group
of Mac-1 ligands. These proteins/peptides, when released
from activated or damaged cells, would alarm the immune
system by triggering responses by binding to Mac-1. The
sequence analyses of Dyn A (YGGFLRRIRPKLKWDNQ)
and Dyn B (YGGFLRRQFKVVT) have indicated that
these peptides contain several Mac-1 binding sites (under-
lined), and thus, may be the Mac-1 candidate ligands.
In the present study we have examined the interactions
of Dyn A and Dyn B with recombinant αMI-domain and
Mac-1-expressing cells and showed that these opioidpeptides are Mac-1 ligands. Further focusing on Dyn A, we
demonstrate that its binding to Mac-1 mediates directed
cell migration of U937 monocytic cells and murine macro-
phages, and enhances phagocytosis by murine macro-
phages. Our results imply that binding of Dyn A to Mac-1
may account for some nonopioid effects of this peptide on
leukocytes. They also suggest that Dyn A may perform dual
functions during neuroinflammation, i.e., produce analgesia
acting via its cognate opioid receptors on neurons and also
alarm the immune cells, causing them to migrate to sites of
tissue injury and activate other leukocyte responses.
Results
Screening of the peptide library spanning the sequence
of dynorphin AB for αMI-domain binding
To test the hypothesis that leukocyte integrin Mac-1
binds opioid peptides, we screened the peptide library
spanning the sequence of dynorphin AB (Fig. 1a) for
αMI-domain binding. The library, consisting of 9-mer
peptides with a 3-residue offset (Fig. 1b) covalently at-
tached to a cellulose membrane, was incubated with the
125I-labeled αMI-domain after which the αMI-domain
binding was visualized by autoradiography and analyzed
by densitometry. The densitometry results demonstrated
that all peptides interacted with the αMI-domain, albeit
to somewhat different extents (Fig. 1b). A control spot
containing only the β-alanine spacer (spot 10) was nega-
tive. The dynorphin-derived peptides were also analyzed
by the computer program IRMA, which determines the
capacity of each peptide in the peptide libraries to inter-
act with the αMI-domain [17]. The program assigns each
peptide the energy value which serves as a measure of
probability that the αMI-domain binds this sequence: the
lower the energy, the higher the likelihood that the se-
quence binds the αMI-domain. As previously determined,
strong αMI-domain binding peptides derived from various
Mac-1 ligands have energy values in the range of −20 to
6 kJ/mole. The analyses showed a good relationship be-
tween the energy scores and the αMI-binding activity of
dynorphin AB-derived peptides revealed in peptide scans
(Fig. 1b). In line with previous findings [17, 18], peptides
enriched in positively charged and hydrophobic residues
had the highest affinities for the αMI-domain (spots 1, 2
and 6 through 10). In particular, the YGGFLRRIR and
FLRRIRPKL peptides (spots 1 and 2), contain the strong
overlapping αMI-domain binding clusters FLRRI and IRP,
which conform to the αMI-domain binding motif
HyHyBHy and HyBHy. The presence of negatively
charged residues in peptides present in spots 3, 4 and 5
weakened their αMI-domain binding activity.
To confirm that αMI-domain binding to dynorphin
AB-derived peptides depends on basic residues and thus
to further substantiate the specificity of the interaction,
























































Fig. 1 Screening of the peptide library spanning the sequence of dynorphin AB for αMI-domain binding. a, Amino acid sequence of dynorphin
AB (residues 1–32). b, Cellulose membrane with the assembled peptide library consisting of 9-mer peptides with three-residue offset was incubated
with 125I-labeled αMI-domain and subjected to autoradiography followed by densitometry. The αMI-domain binding was observed as dark spots. Spot
#10 contains only the β-Ala spacer. The αMI-domain binding was expressed as a percentage of binding to peptide #1, which was assigned a value
100 % and is shown as the numbers on the right of each sequence. The peptide energies that serve as a measure of probability each peptide can
interact with the αMI-domain were calculated as described [17]
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(Additional file 1: Figure S1). The results demonstrated
that mutations of a single basic residue resulted in a
decrease of peptide’s ability to bind the αMI domain and
double or triple mutations within 9-mer peptides abol-
ished αMI domain binding. Together, these results indi-
cate that two non-overlapping sections of dynorphin AB,
encompassing the sequences of Dyn A and Dyn B,
contain the αMI-domain binding sites.
Binding of the αM I-domain to dynorphin A is
activation-independent
Previous studies demonstrated that the αMI-domain ex-
ists in two different conformations, active and nonactive,
with the length of the C-terminal α7 helix regulating its
activation state [19]. Screening of the peptide libraries in
the experiments above was performed using the active
form of the αMI-domain, which encompasses residues
αMGlu
123-Lys315. We produced the active and nonactive
forms of the αMI-domain (αMGln
119-Glu333) (Fig. 2a) asfusions with GST and compared their binding to immo-
bilized Dyn A using solid-phage binding assays. As
shown in Fig. 2b, there was no significant difference be-
tween the two αMI-domains. As a control, binding of
GST to Dyn A was less than 5 % of the αMI-domains
(not shown). As another essential control, the binding of
active αMI-domain to the fibrinogen D100 fragment, the
activation-dependent Mac-1 ligand [18], was ~3.5-fold
higher than that of the nonactive form (Fig. 2c). These
results indicate that the αMI-domain binding to Dyn A is
not activation dependent.
Dynorphins A and B support cell adhesion
The ability of the αMI-domain to bind Dyn A and Dyn B
suggests that these peptides can interact with the whole
receptor expressed on cells. A standard approach to test
the interaction between Mac-1 and their ligands is an
adhesion assay in which HEK293 cells stably transfected
with Mac-1 are examined for their ability to bind the
immobilized ligands [20, 18]. As shown in Fig. 3a, Mac-
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Fig. 2 Binding of the active and nonactive αMI-domain conformers to dynorphin. a, the 3D structure of active (PDB ID 1ido) and nonactive (PDB
ID 1jlm) αMI-domains are shown as ribbon diagrams. The wells of microtiter plates were coated with different concentrations of dynorphin A
(b) and the D100 fragment of fibrinogen (c). The active (●) and nonactive (○) recombinant αMI-domains containing GST fusion parts were added
to the wells and incubated for 1.5 h at 22 °C. Bound αMI-domains were detected with an anti-GST mAb followed by an AP-conjugated secondary
antibody. Data are the means of triplicate determinations, and error bars represent S.E. Representative experiments in b (n = 4) and c (n = 4) are
shown. For multiple comparisons, individual concentrations were tested using t-test with p-value of 0.05 corrected by Bonferroni method and
accepting values of 0.007 as significant (**). No significant difference in binding of active and nonactive αMI-domains to Dyn A was found
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Dyn A. Cell adhesion was dose-dependent with saturable
adhesion achieved with the coating concentration of
peptide at ~2 μM. By contrast, wild-type HEK293 cells
adhered only slightly to Dyn A, indicating that β1 in-
tegrins, the major group of integrins on these cells, min-
imally contribute to adhesion. As additional controls,
HEK293 cells expressing the homologous β2 integrin
LFA-1 (αLβ2, CD11a/CD18) or the I-less form of Mac-1
adhered to Dyn A less efficiently (13 ± 2 % and 7 ± 1 %,
respectively) (Fig. 3b). Control peptide DIDPKLKWD
also failed to support adhesion of Mac-1-HEK293 cells
(not shown). To further establish the specificity of Mac-
1 binding to Dyn A, several anti-Mac-1 reagents were
tested for their ability to inhibit adhesion. Function-
blocking mAb 44a directed against the αM integrin sub-
unit and the specific inhibitor of Mac-1, NIF, inhibited
adhesion of Mac-1-HEK293 cells (Fig. 3c). At 2 μM of
Dyn A, mAb 44a and NIF inhibited adhesion by 81 ±
8 % and 65 ± 7 %, respectively. However, inhibition was
not complete, suggesting that other cell structures are
involved in binding.
We previously demonstrated that soluble heparin
inhibits cell adhesion to several Mac-1 peptide ligands,indicating that cell surface heparan sulfate proteoglycans
(HSPGs) cooperate with Mac-1 [21, 22]. Since Dyn A is
a highly positively charged molecule and is expected to
interact with negatively charged HSPGs, we examined the
involvement of HSPGs in adhesion of Mac-1-expressing
HEK293 cells to Dyn A. The wells, coated with 2 μM Dyn
A, were incubated with heparin for 20 min and cells were
added. As shown in Fig. 3c, heparin at 10 μg/ml exhibited
slight inhibition, but the combination of heparin with
either mAb 44a or NIF produced almost complete in-
hibition (≥95 %) suggesting that cell surface HSPGs are
involved in Mac-1-mediated adhesion to Dyn A. Two
other less negatively charged glycosaminoglycans, chon-
droitin sulfate A and B, were tested alone or in combin-
ation with NIF and found to not exert a statistically
significant inhibitory effect (Fig. 3c).
Figure 3d shows that Mac-1-HEK293, but not wild-
type HEK293 cells, adhered to immobilized Dyn B; how-
ever, on a molar basis, higher coating concentrations of
the peptide compared to Dyn A were required for cell
adhesion to occur. While ~0.2-0.5 μM of Dyn A was
required to reach 50 % of maximal cell adhesion, the
same extent of adhesion occurred at ~7.5 μM of Dyn B.
















































































































































Fig. 3 (See legend on next page.)
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Fig. 3 Adhesion of Mac-1-expressing cells to Dyn A and Dyn B. a, Mac-1-expressing and wild-type HEK293 cells were labeled with calcein and
5x104 cells were added to the wells coated with different concentrations of the Dyn A. After 30 min at 37 °C, nonadherent cells were removed
and fluorescence was measured. The data shown are means of triplicate determinations, and error bars represent S.E. The figure is representative
of 8 experiments. b, adhesion of HEK293 cells expressing Mac-1, LFA and the I-less form of Mac-1 to Dyn A and Dyn B immobilized at 10 μM was
determined as described in A. c, calcein-labeled Mac-1-HEK293 cells were preincubated without or with 10 μg/ml of anti-αM mAb 44a or 1 μg/ml
NIF for 15 minutes. For testing the role of glucosaminoglycans in cell adhesion, dynorphin A-coated wells were preincubated with 100 μl of 10 μg/ml
of chondroitin sulfate A, chondroitin sulfate B and heparin. Aliquots (5x104cells) were added to the wells coated with 2 μM dynorphin A and adhesion
was performed as described in A. Adhesion in the absence of Mac-1 inhibitors and glucosaminoglycans was assigned a value of 100 %. The
data shown are the means ± S.E. from four separate experiments each with triplicate measurements. d, microtiter plate wells were coated with
different concentrations of dynorphin B and adhesion of Mac-1-expressing and wild-type HEK293 cells was determined as described in A. The
data shown are means of triplicate determinations, and error bars represent S.E. The figure is representative of 5 experiments. e. calcein-labeled
Mac-1-HEK293 cells were preincubated without or with 10 μg/ml of mAb 44a and heparin, added to the wells coated with 20 μM of dynorphin
B and adhesion was performed as described in A. Adhesion in the absence of inhibitors was assigned a value of 100 %. The data shown are the
means ± S.E from three separate experiments each with triplicate measurements. **p < 0.01; ns, no significant difference
Podolnikova et al. Molecular Pain  (2015) 11:33 Page 6 of 16I-less form of Mac-1 failed to adhere to Dyn B (Fig. 3b).
Similar to Dyn A, cell adhesion was partially inhibited
by anti-αM mAb 44a (52 ± 4 %) and effectively blocked
by 84 ± 1 % in the presence of mAb 44a and heparin
(Fig. 3d). Taken together, these observations indicate
that both Dyn A and Dyn B fulfill the specification of
typical Mac-1 ligands.
Soluble dynorphins inhibit cell adhesion to the Mac-1
ligand fibrinogen
The ability to inhibit cell adhesion is a characteristic of
peptide ligands of Mac-1 [22, 23]. Consequently, we tested















Fig. 4 Effect of soluble Dyn A on Mac-1-mediated cell adhesion to fibrinog
bated with different concentrations of dynorphin A (black bar), dynorphin
added to the wells of microtiter plates coated with 2.5 μg/mL fibrinogen. C
nonadherent cells. Data are expressed as a percentage of control adhesion
ual experiments performed with triplicate determinations in each experime
expressing HEK293 cells were preincubated with dynorphin A and B as des
natants was determined. Data are expressed as a percentage of total cell flMac-1-HEK293 cells to fibrinogen, the representative
Mac-1 ligand [18, 20]. Dynorphins inhibited adhesion
to immobilized fibrinogen in a concentration-dependent
manner (Fig. 4) with Dyn A exhibiting a somewhat higher
activity than Dyn B (67 ± 2 % and 56 ± 11 % at 50 μM for
Dyn A and B, respectively). Control peptide DIDPKLKWD
was only slightly inhibitory.
Previous investigations reported that Dyn A, but not
Dyn B, enters the cells [24]. Therefore, we first examined
whether these peptides at the concentrations used in
adhesion and inhibition experiments described above
can affect the membrane integrity causing the leakage of










en. a (left ordinate), calcein-labeled Mac-1-HEK293 cells were preincu-
B (open bar) or control peptide (gray bar) for 10 min at 22 °C and
ells were allowed to adhere for 30 minutes at 37 °C before removing
(in the absence of peptides) and are the mean ± S.E. of three individ-
nt. **p < 0.01; ns, no significant difference. b (right ordinate), Mac-1-
cribed in A, centrifuged for 5 min at 500 × g and fluorescence of super-
uorescence
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giving a false impression of reduced adhesion. As shown
in Fig. 4, no leakage of calcein was detected using both
dynorphins, indicating that soluble peptides inhibited
adhesion by blocking Mac-1.
To investigate whether Dyn A translocates into cells,
we incubated Mac-1-HEK293 and wild-type HEK293
cells with increasing concentrations of Dyn A for 40 min
at 37 °C, which corresponded to the total time the cells
were exposed to Dyn A in our cell adhesion assays. Cells
were then fixed and labeled with anti-dynorphin anti-
bodies. As shown in Fig. 5a-d, a significantly smaller













Fig. 5 Translocation of Dyn A into cells. Mac-1-expressing (a) and wild-type
for 40 min at 37 °C, fixed, permeabilized and incubated with anti-dynorphi
anti-rabbit antibodies. No labeling was detected in the absence of primary
wild-type HEK cells shown in a and b. d, Quantification of fluorescent cellscompared to wild-type HEK293 cells. Moreover, at
20 μM, Dyn A was primarily associated with the cell
periphery of the Mac-1-HEK293 cells while entering in-
side wild-type HEK293 cells (Fig. 5c). This finding sug-
gests that the presence of Mac-1 on the cell surface may
retard translocation of Dyn A across the membrane,
most likely by Dyn A binding to Mac-1.
Migration of Mac-1-expressing cells to Dyn A
Previous studies demonstrated that Dyn A (residues 1–
13) was capable of inducing cell migration [25, 26]. To
investigate the relationship between Mac-1, Dyn A and



























HEK293 (b) cells were incubated with 20 μM and 100 μM of Dyn A
n antibodies followed by Alexa Fluor 488-conjugated secondary goat
antibody. c, Enlarged images of Dyn A-accumulated Mac-1- and
shown in a and b
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Dyn A in a transwell system. These cell lines were re-
ported to be a useful system for assessing the role of
Mac-1 in migration [27, 28]. The cells were placed in
the upper chambers with different concentrations of
Dyn A in the lower chambers, and cells were allowed to
migrate for 16 h at 37 °C. As shown in Fig. 6a, Dyn A
induced a strong concentration-dependent migratory re-
sponse. The concentrations as low as 0.5-1 μM induced
migration of Mac-1-HEK293 cells with the response
reaching saturation at 5 μM. Wild-type HEK293 cells
did not migrate to Dyn A and Mac-1-HEK293 cells mi-
grated only slightly to the medium without peptide
(Fig. 6b). Direct evidence that migration of Mac-1-
HEK293 cells was dependent on Mac-1 was obtained in
the experiments in which anti-Mac-1 function blocking
mAbs were tested (Fig. 6b). The mAbs 44a and IB4
against the αM and β2 integrin subunits, respectively,
eliminated cell migration, while non-blocking anti-αM
mAb OKM1 had no effect.
In another set of experiments using the transwell mi-
gration system, we evaluated migration of macrophages
isolated from the peritoneum of wild-type and Mac-1-
deficient mice. Purified macrophages were allowed to
migrate through the 5-μm pore filter for 90 min at 37 °C.
As shown in Fig. 6c, whereas wild-type microphages
migrated to Dyn A, migration of Mac-1-deficient cells
was significantly impaired.
The ability of Dyn A to support Mac-1-mediated cell
migration was further confirmed using a chemotaxis
migration system in which cells migrate to agar gels
impregnated with a chemotactic agent (Fig. 7a). In these
experiments, Mac-1-expressing U937 monocytic cells
efficiently migrated along the gradient of Dyn A with
many cells arriving at the edge of the gel (Fig. 7b, upper
panel). In contrast, no directional migration was ob-
served when Dyn A was absent (Fig. 7b, bottom panel);
cells remained stationary and were evenly distributed at
their initial position on the coverslip. Preincubation of
cells with mAb 44a resulted in inhibition of their migra-
tion compared to nontreated control cells with only few
cells arriving to the Dyn A-containing drop (Fig. 7b). As
shown in Fig. 7c, only ~ 15 % of cells moved from the
initial field in the presence of mAb 44a, implicating
Mac-1 in mediating the chemotactic response of U937
cells to Dyn A.
Leukocytes, including U937 monocytic cells, are known
to express G-protein coupled κ-opioid receptors for Dyn
A [8]. Therefore, we also examined the effect of naloxone,
the inhibitor of these receptors. In control experiments,
we have found that naloxone does not affect Mac-1 medi-
ated cell adhesion suggesting that it does not interact with
the ligand-binding site of the αMI-domain (not shown).
Added at 10 μM, naloxone inhibited emigration of cellsfrom the starting point, but the effect was less potent
than mAb 44a, with ~20 % remaining at the start (Fig. 7b
and c). However, although naloxone was a less potent
inhibitor it still affected migration down the migratory
path since only a few cells arrived to the Dyn A-
containing drop. Therefore, we have analyzed the distri-
bution of cells treated with either 44a or naloxone along
the chemotactic gradient by determining the number of
cells in each of 10 consecutive 1-mm fields. These cal-
culations produced a Gaussian distribution of cells as a
function of the distance from the starting point (Fig. 7d).
The analyses demonstrated that both 44a and naloxone
inhibited migration: however, while the mean distance
travelled by naloxone-treated cells was ~5 mm, the
mAb 44a-treated cells migrated only ~3.5 mm. The ma-
jority of untreated cells traveled ~8-mm towards the
Dyn A-containing drop. Together, these results indicate
that Dyn A can trigger both Mac-1 and κ-opiod recep-
tor responses.
Dyn A augments phagocytosis of plastic beads via Mac-1
We hypothesized that Dyn A immobilized on the surface
of plastic beads may bind to Mac-1 on macrophages
followed by their phagocytosis. To examine this possibil-
ity, control and Dyn A-treated fluorescent 1 μm beads
were incubated with adherent IC-21 murine macrophages
at a ratio of 20:1 for 30 min (a saturation time determined
in preliminary experiments) and their phagocytosis was
determined (Fig. 8a). Quantification of phagocytosed
beads indicated that Dyn A augmented uptake by ~ 10-
fold (Fig. 8b). To investigate whether integrin Mac-1 on
macrophages is involved in promoting phagocytosis of
Dyn A-coated beads, we examined the effects of mAb
M1/70 (against murine αM) and NIF. On their own, mAb
M1/70 and NIF strongly inhibited Dyn A-mediated phago-
cytosis by ~ 85 % and ~ 70 %, respectively (Fig. 8b). In con-
trast, heparin and naloxone did not decrease the number
of phagocytosed beads, and an isotype control IgG2b for
mAb M1/70 had no effect. Together, these results indicate
that Dyn A is capable of enhancing macrophage phagocyt-
osis via interaction with integrin Mac-1.
Discussion
In the present study we identified opioid peptides Dyn A
and Dyn B as novel ligands for leukocyte integrin Mac-1.
In support of this finding, we showed that recombinant
αMI-domain, a ligand binding region of Mac-1, interacts
with Dyn A- and Dyn B. Expression of Mac-1 in HEK293
cells resulted in Mac-1-mediated cell adhesion to immobi-
lized Dyn A and Dyn B, while related integrin LFA-1
(αLβ2, CD11a/CD18) or Mac-1 in which the αMI-domain
was deleted by genetic manipulation, supported a signifi-
cantly lower level of adhesion to Dyn A and did not bind
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Fig. 6 Migration of Mac-1-expressing cells to Dyn A in a Transwell
system. a, Mac-1-expressing HEK 293 cells (100 μl at 3 × 106 cell/ml)
were added to the upper wells of the transwell chamber and their
ability to migrate to different concentrations of Dyn A placed in the
lower chamber was analyzed. After 16 hours at 37 °C, migrated cells
were fixed, stained, and counted. Data are presented as numbers of
migrated cells per field ± S.E. for five random fields per well. The
figure is representative of 5 experiments. b, Mac-1-expressing or
wild-type HEK 293 cells were added to the upper wells of the
transwell chamber and their ability to migrate to 10 μM Dyn A placed
in the lower chamber was analyzed as in A. Some Mac-1-HEK293 cells
were pretreated with 20 μg/ml of mAbs 44a (anti-αM), IB4 (anti-β2)
or OKM1 (non function-blocking anti-αM) or medium alone before
addition to the upper wells. ***, medium alone. Data are presented as
the number of migrated cells per field ± S.E. for five random fields/well
from 3 separate experiments. **, p < 0.01. c, migration of TG-elicited
macrophages isolated from the peritoneum of wild-type and Mac-1-
deficient mice. Macrophages (3x105) were placed in the upper
chamber and allowed to migrate to Dyn A (10 μM) in the lower
chamber for 90 min. The number of migrated cells was determined
as in A. Data are presented as number of migrated cells per field ±
S.E. for five random fields per well. The figure is representative of
3 experiments
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macrophages, which are entirely dependent on Mac-1. In
U937 monocytic cells, the Mac-1-mediated migration was
partially inhibited by naloxone, suggesting the involvement
of both Mac-1 and opioid receptors. In addition, Dyn A
enhanced phagocytosis of latex beads by murine macro-
phages in a Mac-1 dependent and naloxone-independent
manner. These observations establish Mac-1 as a receptor
for Dyn A and Dyn B and suggest a role for the Mac-
1-Dyn A interactions in the induction of nonopioid
receptor-dependent effects in leukocytes.
The characteristic feature of Mac-1 ligands is the pres-
ence of basic residues surrounded by hydrophobic resi-
dues which form short αMI-domain recognition motifs
[17, 18]. The sequences enriched in such motifs are
abundant in many cationic proteins and peptides that
are stored in neutrophil granules, including elastase,
myeloperoxidase, cathepsin G and others. Inspection of
the Dyn AB (residues 1–32) sequence revealed that it
contains several typical αMI-domain recognition motifs
in both the N-terminal and C-terminal parts, including
4FLRRIRPKLK13 and 23FLRRQFKVV31, suggesting that
Dyn A and Dyn B, encompassing residues 1–17 and 20–32,
respectively, may be Mac-1 ligands. Indeed, screening of
the peptide libraries spanning the sequence of Dyn AB
showed that recombinant αMI-domain interacted with
many overlapping peptides, with somewhat higher
affinity for those spanning the sequences of Dyn A and
Dyn B (Fig. 1b). The αMI-domain binding to dynorphin-
derived peptides was specific inasmuch as mutations of
positively charged residues, the critical determinants
of the αMI-domain recognition specificity, strongly re-








































































Fig. 7 Chemotactic response of U937 cells to Dyn A. a, schematic representation of the experimental format. U937 cells (5x104) were placed in
the center of the coverslip between two agar gels, one containing Dyn A and control gel without Dyn A. After 2 h at 37 °C, a series of photographs
was taken in the direction of migration at 1-mm intervals to count the number of migrating cells. b, representative images after 2 h of migration show
the cells within the starting point (marked with a cross; right panels) and at the border of the Dyn A-containing agar drop (left panels). Some
cells were incubated with mAb 44a (20 μg/ml) or naloxone (10 μM) for 30 min before the initiation of chemotaxis assays. Two bottom panels
show the experimental condition with no Dyn A gradient. c, quantification of U937 cells migrated from the initial point after 2 h based on the
results shown in A (right panel). Migration of control untreated U937 cells that completely migrated from the initial point of cell placement was
assigned a value of 100 %. In contrast, there was no cell migration without a Dyn A gradient (0 %). Migration of cells preincubated with mAb
44a and naloxone was blocked by ~80 % and ~20 %, respectively. A representative experiment is shown. d, distribution of U937 cells between
two gels: Dyn A-containing (on the left) and without Dyn A (on the right). “0” on abscissa corresponds to the initial point where cells were
loaded and the numbers show the distance that cells migrated in both directions from the starting point. All cells in each of 10 consecutive
fields towards the Dyn A-containing and empty gels were counted and plotted as a distance from the starting point





































Fig. 8 Effect of Dyn A on phagocytosis of latex beads. a, Fluorescent latex beads (1x109/ml) were preincubated with Dyn A (50 μg/ml) for 40 min
at 37 °C. Soluble peptide was removed from the beads by high-speed centrifugation. Peptide-coated beads were incubated with adherent IC-21
macrophages for 30 min at 37 °C. Nonphagocytosed beads were removed from cells by washing with PBS. IC-21 cells exposed to control (left)
and Dyn A-treated (right) beads are shown. b, Peptide-coated beads were incubated with IC-21 macrophages in the presence of anti-αM mAb
M1/70 (20 μg/ml), heparin (20 μg/ml), NIF (2 μg/ml) or naloxone (10 μM). Rat IgG2b was used as an isotype control for anti-αM mAb M1/70.
Phagocytosis was quantified for five random fields per well using a 20x objective. Phagocytosis of Dyn A-treated beads was assigned as 100 %.
Data shown are mean ± S.E. from three separate experiments. **p < 0.01; ns, no significant difference
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sion assays in which Dyn A and Dyn B supported effi-
cient adhesion of Mac-1 expressing cells. The specificity
of Mac-1 interaction with Dyn A and Dyn B has been
further confirmed by blocking the interaction with anti-
Mac-1 reagents. Consistent with our previous results in
other Mac-1-ligand systems [21, 22], soluble heparin
potentiated the inhibitory effect of function-blocking
anti-Mac-1 mAb suggesting that cell surface HSPGs
may cooperate with Mac-1 in recognition of positively
charged dynorphins. The behavior of Dyn A and Dyn B
in the experiments with isolated αMI-domain and whole
receptors expressed on cells recapitulates that of other
well-characterized Mac-1 peptide ligands, including thefibrinogen peptide γ383TKIIPFNRLTIG395 (P2-C) [23,
18] and the growth factor CCN1-derived peptide
SSVKKYRPKYCGS (CCN1-H2) [22], both of which
contain typical αMI-domain recognition motifs.
Numerous studies reported that Dyn A has immuno-
modulatory properties and elicits various responses in
cultured cells and isolated murine macrophages, includ-
ing migration, phagocytosis, oxidative burst, degranula-
tion and expression of cytokines [5, 7, 9, 14, 15]. Dyn A
binds preferentially to the k-opioid receptors that have
been identified on resting mouse macrophages, macro-
phage cell lines and neutrophils (Reviewed in [29–31]).
In addition to the k-opioid receptors, for which Dyn A
shows higher affinity, it can bind to μ- and δ-opioid
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cytes/macrophages from several species [30]. However,
many responses induced by Dyn A in myeloid cells are
naloxone-insensitive [7, 11, 15] suggesting that it can
interact with other receptors. Macrophages and neutro-
phils abundantly express integrin Mac-1 (CD11b/CD18),
which is a common marker of these cells. It is well
known that ligand engagement by Mac-1 initiates intra-
cellular signaling that regulates many leukocyte re-
sponses [16, 33]. A striking similarity between responses
induced in macrophages and neutrophils by Dyn A and
by many Mac-1 ligands suggests that binding of Dyn A
to Mac-1 may mediate non-opioid reactions. Further-
more, Dyn A induces degranulation of mast cells, which
also express Mac-1 [34], suggesting that in these cells
Dyn A may act through Mac-1.
Consistent with the idea that Dyn A may mediate re-
sponses via Mac-1, migration of Mac-1-expressing
HEK293 cells was completely blocked by anti-Mac-1
function-blocking antibodies (Figs. 6 and 7). HEK293
cells transfected with Mac-1 are often used in structural
and functional analyses of this integrin to avoid the con-
founding effects of other leukocyte receptors. An add-
itional advantage of these cells is that they do not
express opioid or NMDA receptors [35] which are also a
target for dynorphins (reviewed in [1]) and which other-
wise may be present on cultured macrophage-like cell
lines or monocytes/macrophages isolated from blood.
Nevertheless, we found that the effect of Dyn A on mi-
gration of thioglycollate-elicited mouse peritoneal mac-
rophages was solely dependent on Mac-1, inasmuch as
wild-type, but not Mac-1-deficient macrophages, mi-
grated to Dyn A. In contrast, migration of human U937
monocytic cells seems to depend on both opioid recep-
tors and Mac-1. Previous studies that assessed expres-
sion of opioid receptors on human peripheral blood
monocytes produced conflicting results. Williams et al.
[36] reported that peripheral blood mononuclear cells
(PBMC) do not display classical opioid receptors, while
another group showed the presence of transcripts for
μ-opiod receptors not only in lymphocytes, which con-
stitute the majority of PBMC, but also in isolated mono-
cytes and neutrophils [37]. It was proposed that even
though resting blood monocytes do not express opioid
receptors, their expression may increase after proinflam-
matory stimulation [36]. Furthermore, cultured U937
monocytic cells may differ from normal cells with regard
to expression of opioid receptors. Although it is clear
that Dyn A binds Mac-1 and induces migration of
Mac-1 expressing cells, the relationship between opioid
receptors and Mac-1 on human peripheral blood mono-
cytes/macrophages remains to be more clearly defined.
Previous studies demonstrated that Dyn A is able to
translocate across the plasma membrane in a number ofcells [24]. In agreement with this observation, we
showed that Dyn A penetrates wild-type HEK293 cells.
However, we also consistently observed that the penetra-
tion of Dyn A was strongly reduced in the Mac-1-
expressing HEK293 cells. Moreover, in these cells, Dyn A
was detected as a rim around the cell periphery suggesting
that binding of Dyn A to Mac-1 may delay translocation
of the peptide. The potential of dynorphins to penetrate
into cells has been proposed to correlate with their ability
to induce non-opioid effects in animals [24]. However, the
fact that Dyn A-induced migration of Mac-1-expressing
HEK293 cells was fully blocked by anti-Mac-1 function-
blocking mAbs suggests that, at least in these cells, the re-
sponse was mediated by binding of Dyn A to Mac-1.
Nevertheless, although the observed pattern of Dyn A dis-
tribution at the plasma membrane of Mac-1-expressing
HEK293 cells may potentially serve as evidence for the
interaction of Dyn A with Mac-1 additional studies may
help to define the role of Mac-1 in translocation of Dyn A
in Mac-1-expressing blood leukocytes.
A distinctive property of Dyn A, as well as other opi-
oid peptides, is that they are stored in neutrophil gran-
ules and in monocyte/macrophages, and released from
these cells upon stimulation by various proinflammatory
agonists (reviewed in [4, 38]). Dynorphins were also
found in mouse monocyte/macrophages recruited to the
site of inflammation [39, 40]. Many cationic proteins
stored in primary (elastase, myeloperoxidase, cathepsin
G and azurocidin) and specific (hCAP18/LL-37) neutro-
phil granules are Mac-1 ligands [17, 41, 42] enriched in
Mac-1 recognition sequences similar to those found in
Dyn A [17]. Furthermore, like Dyn A, they induce im-
munomodulatory responses in monocyte/macrophages
[43–45]. It is well known that the neutrophil influx from
the circulation represents the first wave of leukocyte mi-
gration to the site of injury followed by a second wave of
monocyte extravasation. It has been proposed that neu-
trophils trigger this cellular switch by releasing granule
products and, thus, pave the way for migration of mono-
cyte/macrophages [46, 47]. It is tempting to speculate
that dynorphins, similar to other cationic peptide/pro-
teins, fulfill a common function of alarming the immune
system by evoking leukocyte responses via Mac-1.
However, further studies in dynorphin knock out mice
are required to investigate whether the interaction of
dynorphins with Mac-1 is biologically relevant.
One important property of Dyn A that is not shared
by other cationic peptide/proteins is that it is a bi-
functional molecule, i.e., it acts directly on opioid recep-
tors and also displays other activities. Similar to other
cationic peptides [48, 49], Dyn A can exert some effects
essential for host defense. Dyn A, and to less extent Dyn
B, have been shown to enhance phagocytosis by mouse
peritoneal macrophages [7]. Interestingly, the phagocytic
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6ArgArgIle8 sequence in Dyn A, which represents a core
structure of the αMI-domain recognition motif. Indeed,
we have shown that Dyn A strongly enhanced phagocytosis
of latex beads by binding to Mac-1 (Fig. 8), a well-known
phagocytic receptor [50, 51]. Dyn A and Dyn B seems to be
unique among opioid peptide family members since in con-
trast to β-endorphin and Met-enkephalin, they contain
readily identifiable sequences typical for the αMI-domain
recognition motifs. Nevertheless, the presence of short
sequences containing lysine and adjacent hydrophobic resi-
dues (LeuPheLys and IleIleLys) in β-endorphin and arginine
surrounded by hydrophobic residues (PheMetArgPhe) in
Met-enkephalin-ArgPhe is intriguing and may warrant the
investigation of their Mac-1 binding potential.
Although neutrophils and macrophages contain Dyn A
which may contribute to eliciting leukocyte responses in
inflamed peripheral tissues, the major source of this pep-
tide is the CNS (reviewed in [1]). The concentration of
Dyn A within dense core vesicles of neurons was esti-
mated to be 1 mM [52] and the levels of the prodynor-
phin precursor within the vesicles appears to be even
higher. It has been proposed that the concentration of
Dyn A within the extracellular space of the CNS is
greater than 10 μM and could significantly increase
following spinal cord or traumatic brain injuries. With
such high levels, it is possible that Dyn A released dur-
ing these pathologies may not only perform its primary
role in pain reduction, but also act as a chemotactic sig-
nal attracting neutrophils and monocytes to sites of in-
jury. Indeed, spinal cord injury is known to induce a
strong inflammatory response with invasion of neutro-
phils and monocytes known as secondary injury [53].
Further studies utilizing dynorphin, KOR and Mac-1
knockout mice are likely to be a useful strategy to investi-
gate the role of dynorphins using the experimental models
of spinal cord injury and other models of inflammation.
The concept that the immune system can communi-
cate with peripheral sensory neurons to modulate pain
has emerged from numerous studies that explored the
role of opioid-containing neutrophils in early inflamma-
tion and monocytes/macrophages at later stages in indu-
cing antinociception [54, 4]. The finding in the present
study that Dyn A and Dyn B are ligands for integrin Mac-
1, the major adhesion and signaling receptor expressed on
myeloid cells, coupled with the data that Dyn A-Mac-1 in-
teractions may initiate proinflammatory responses in these
cells, establishes a hitherto unrecognized molecular link
between opioid and immune systems, affording new
insights into the function of the neuro-immune axis.
Although the precise role of Dyn A in triggering Mac-1-
mediated immunomodulatory reactions remains to be
further defined in vivo, the fact that the amino acid
sequence of Dyn A and Dyn B is highly conservedevolutionarily [55] may point to a special role of these
multifunctional peptides in the complex network of opi-
oid peptides and their receptors on immune cells.
Conclusions
The results from these studies identify opioid peptides
dynorphin A and B as novel ligands for leukocyte integ-
rin Mac-1 (αMβ2, CD11b/CD18). We have found that
both dynorphin A and B contain typical recognition mo-
tifs for the αMI-domain, the ligand binding region of
Mac-1, and demonstrated that both opioid peptides dir-
ectly interact with recombinant αMI-domain and whole
receptors expressed on cells. Focusing further on dynor-
phin A, we have shown that at variance with other Mac-
1 ligands, dynorphin A does not require the active state
of the αMI-domain. In functional assays, dynorphin A
can support a Mac-1-mediated chemotactic cell migra-
tion and enhance phagocytosis by murine macrophages
by binding to Mac-1. These findings suggest a role for
the Mac-1-Dyn A interactions in the induction of nono-
pioid receptor-dependent effects in leukocytes.
Methods
Peptides, proteins and monoclonal antibodies
Dyn A (YGGFLRRIRPKLKWDNQ), Dyn B (YGGFLR
RQFKVVT), and control peptide (DIDPKLKWD) were
purchased from AnaSpec, Inc (San Jose, CA). Fibrinogen,
depleted of fibronectin and plasminogen, was obtained
from Enzyme Research Laboratories (South Bend, IN).
The D100 (mol. weight 100,000 Da) fragment of fibrinogen
was prepared by digestion of fibrinogen with plasmin [56].
The mAbs 44a and OKM1, directed against the αM-integ-
rin subunit and mAb IB4, directed against the β2-integrin
subunit, were purified from the conditioned media of the
hybridoma cell lines obtained from ATCC (Manassas, VA)
using protein G agarose (GenScript, Piscataway, NJ). Poly-
clonal anti-Dyn A antibody (ab 82509) was from Abcam
(Cambridge, MA). Neutrophil inhibitory factor (NIF) was
a gift from Corvas International. The anti-GST mAb was
purchased from Pierce Precision Antibody (Rockford, IL).
BSA, polyvinylpyrrolidone (PVP), fMLP, heparin, and
chondroitin sulfate A and B were obtained from Sigma
(St. Louis, MO). Calcein AM was purchased from
Molecular Probes (Life Technologies, Grand Island, NY).
Recombinant αMI-domains in the active (residues Glu
123-
Lys315) and non-active conformation (residues Gln119-
Glu333) were expressed and purified from E. coli lysates as
fusion proteins with glutathione S-transferase (GST) using
affinity chromatography as previously described [57].
Synthesis of cellulose-bound peptide libraries
Peptide libraries derived from dynorphin AB assembled
on cellulose membrane supports were prepared by parallel
spot synthesis as previously described [58, 18]. Peptides
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spacer and were acetylated N-terminally. The membrane-
bound peptides were tested for their ability to bind the
αMI-domain according to a previously described proced-
ure [18]. In brief, the membrane was blocked with 1 %
BSA and then incubated with 10 μg/ml of 125I-labeled
αMI-domain in TBS containing 1 mM MgCl2. After wash-
ing, the membrane was dried and the αMI-domain binding
was visualized by autoradiography.
Solid-phase binding assays
Microtiter plates were coated with different concentra-
tions of the fibrinogen D100 fragment or Dyn A over-
night at 4 °C and post-coated with 3 % BSA for 1 h. The
GST-αMI-domains in 20 mM Tris–HCl, pH 7.4,
100 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 0.05 %
Tween 20, and 5 % glycerol were added to the wells and
incubated for 1.5 h at 22 °C. After washing, the plates
were incubated with an anti-GST mAb at a 1:5000 dilu-
tion for 1 h at 22 °C. After washing, goat anti-mouse
IgG conjugated to alkaline phosphatase was added for
1 h and the binding of the αMI-domains was detected by
reaction with p-nitrophenyl phosphate measuring the
absorbance at 405 nm. Background binding to BSA was
subtracted.
Cells
Human embryonic kidney cells (HEK293), Mac-1-ex-
pressing HEK293 cells (Mac-1-HEK293), LFA-1 (CD11a/
CD18) and HEK293 cells expressing the αM subunit
lacking the αMI-domain [20] were maintained in DMEM
(Mediatech Inc, Manassas, VA) supplemented with 10 %
fetal bovine serum and antibiotics. U937 monocytic
cells were grown in RPMI containing 10 % fetal bovine
serum and antibiotics. Neutrophils were isolated under
sterile conditions from human peripheral blood ob-
tained from consenting volunteers as described [59].
Peritoneal macrophages were isolated from wild-type
and Mac-1-deficient mice (The Jackson Laboratories)
3 days after the injection of 4 % thioglycollate (TG).
Macrophages were separated from lymphocytes using a
mouse PE selection kit (STEMCELL Technologies, Van-
couver, BC, Canada).
Cell adhesion
Adhesion assays were performed essentially as described
previously [28, 20]. Briefly, the wells of 96-well polyster-
ene microtiter plates (Immulon 4HBX, Thermo) were
coated with various concentrations of Dyn A peptide,
Dyn B, control peptide, or D100 fibrinogen fragment for
3 h at 37 °C, and then post-coated with 1 % PVP for 1 h
at 37 °C. Cells were labeled with 10 μM calcein for
30 min at 37 °C and washed twice with Hanks’ Balanced
salt solution (HBSS) containing 0.1 % BSA. Aliquots(100 μl) of labeled cells (5x105/ml) were added to each
well and allowed to adhere for 30 min at 37 °C. The
non-adherent cells were removed by two washes with
PBS. Fluorescence was measured in a CytoFluorII fluor-
escence plate reader (Perceptive Biosystems, Framing-
ham, MA). In inhibition experiments, cells were mixed
with different concentrations of peptides, NIF or mAbs
for 20 min at 22 °C before they were added to the wells
coated with adhesive substrates. In a separate set of
experiments, after coating plates with dynorphins and
post-coating with 1 % PVP, plates were incubated with
100 μl of 10 μg/ml chondroitin sulfate A, chondroitin
sulfate B, or heparin for 20 min at 22 °C. After aspirating
the solution, labeled cells were added and cell adhesion
was analyzed as above.
Phagocytosis assays
A suspension of fluorescent 1.0 μM latex beads (1x109/ml)
(FluoSpheres sulfate microspheres, Life Technologies,
Carlsbad, CA) was incubated with 50 μg/ml of Dyn A for
40 min at 37 °C, then unbound peptide was removed by
centrifugation. IC-21 murine macrophages (5 × 105/ml)
were adhered on the cover glass for 30 min and 3 × 106 of
peptide-coated beads were added to adherent IC-21 cells.
After incubating for 30 minutes at 37 °C, nonphagocy-
tosed beads were separated from macrophages by washing
with 3x1 ml PBS and phagocytosed beads were counted in
the presence of trypan blue. In inhibition experiments,
cells were mixed with mAbs, NIF, heparin or naloxone for
15 min at 22 °C before addition of the fluorescent beads.
The ratio of beads per macrophage was quantified by tak-
ing photographs of five fields for each well using a Leica
DM4000 B microscope (Leica Microsystems, Buffalo
Grove, IL) with a 20 × objective.
Transwell migration assays
Migration assays with wild-type and Mac-1-expressing
HEK293 cells and purified macrophages using Transwell
inserts (5 μm pore size) were performed as previously
described [27, 28]. Briefly, cells (3 × 105) were placed in
the upper chamber of the Transwell system and lower
chambers contained 600 μl of DMEM medium + 10 μM
Dyn A. For inhibition experiments, cells were pretreated
with 20 μg/ml of each function blocking anti-αM mAb
44a, anti-β2 mAb IB4 or noninhibitory mAb OKM1 for
30 min before their addition to the upper chamber of
the transwell system with 10 μM Dyn A in the lower
chamber. Migration was allowed to proceed for 16 h and
90 min for Mac-expressing HEK293 cells and macrophages,
respectively, at 37 °C. The cells in the upper wells were
removed by wiping with a cotton swab and cells ad-
herent to the underside of the filter were fixed with
paraformaldehyde and stained with Hematoxylin. The
photographs were taken using a 20x objective and cells
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three experiments.
Chemotaxis migration assay
Chemotaxis assays using U937 monocytic cells were per-
formed on 22 × 22 mm cover slips. 1 % agarose (Life
Technologies, Carlsbad, CA) was dissolved in HBSS by
heating. After cooling, the agarose solution was mixed
with Dyn A to obtain a final concentration of 10 μM. A
10 μl drop of warm agarose solution containing Dyn A
was placed at one corner of the cover glass at ~1.5 mm
from the edge. A control agarose drop was placed diag-
onally at the opposite corner of the cover glass. Agarose
was allowed to solidify for 5 min, and the cover glasses
were placed into wells of the 6-well plate filled with 5 ml
of RPMI 1640 + 10 % FBS. A 10-μl aliquot of U937 cells
(5x104) was loaded in the center of the cover glass and
the plate was incubated for 2 h at 37 °C in a humidified
atmosphere containing 5 % CO2. In this experimental
format, the cells sediment approximately 5 min after
loading, forming an ~4 mm circle, and begin to migrate
towards the Dyn A-containing agarose drop. In inhib-
ition experiments, cells were incubated with 44a (20 μg/
ml) or Naloxone (10 μM) for 30 min before adding them
to the cover glass. The photographs were taken at 1-mm
intervals in the direction of cell migration towards the
dynorphin-containing or control agarose drops without
dynorphin A. The number of cells at the starting point
and in each of 10 consecutive fields towards the
dynorphin-containing and empty gels were counted and
plotted as a distance from the starting point.
Immunolabeling of dynorphin A translocated into cells
Mac-1-HEK 293 and wild-type HEK 293 cells were incu-
bated for 10 min with different concentrations (0–100 μM)
of Dyn A and allowed to adhere to glass coverslips coated
with poly-Lysine for 30 min. Adherent cells were fixed in
2 % paraformaldehyde solution, permeabilized with 0.1 %
Tween-20, and blocked with 10 % normal goat serum plus
1 % BSA. The coverslips were incubated with 5 μg/ml
polyclonal anti-Dyn A antibody followed by an secondary
goat anti-rabbit antibody conjugated to Alexa Fluor 488
(1:1000). Images were taken using a Leica DM 4000B
microscope (Leica, Buffalo Grove, IL).
Statistical analysis
All data are presented as the mean ± S.E. The statistical
differences between two groups were determined using a
Student’s t-test from SigmaPlot 11.0 software (Systat
Software, San Jose, CA). For multiple comparisons, the
Bonferroni correction method was used. Differences
were considered significant if p-value was less than 0.05.Additional file
Additional file 1: Figure S1. Identification of residues in dynorphin A
critical for αMI-domain binding. The dynorphin AB-based substitutional
peptide libraries with single, double or triple mutations of basic residues
were prepared by SPOT synthesis as described in Experimental Procedures.
Mutated amino acid residues are shown in red. The membranes with
synthesized peptide libraries were incubated with 125I-labeled αMI-domain
and subjected to autoradiography. The αMI-domain binding was analyzed
by densitometry and expressed in arbitrary units with the strongest binding
to wild-type peptides assigning a value of 4+. The peptides that partially
lost their ability to bind the αMI-domain were grouped according to
their activity and marked as 3+, 2+ and +. The peptides that lost their
ability to bind the αMI-domain are marked with “NB “.
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